Compare JBLU & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBLU | EVO |
|---|---|---|
| Founded | 1998 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 994.5M |
| IPO Year | 2002 | N/A |
| Metric | JBLU | EVO |
|---|---|---|
| Price | $4.87 | $2.81 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 13 | 1 |
| Target Price | $4.91 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 23.4M | 40.1K |
| Earning Date | 04-28-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.83 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,062,000,000.00 | N/A |
| Revenue This Year | $12.11 | $1.37 |
| Revenue Next Year | $6.75 | $10.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.87 | $2.31 |
| 52 Week High | $6.46 | $4.42 |
| Indicator | JBLU | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 43.13 |
| Support Level | $4.51 | $2.63 |
| Resistance Level | $5.15 | $3.82 |
| Average True Range (ATR) | 0.24 | 0.07 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 36.99 | 21.62 |
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.